Market Overview

Bank of America Merrill Lynch Reiterates Buy Rating, $64 PT on Quest Diagnostics

Related DGX
Quest Diagnostics Added To Goldman Sachs Conviction Buy List
Top 4 NYSE Stocks In The Medical Laboratories & Research Industry With The Highest Dividend Yield

In a report published Wednesday, Bank of America Merrill Lynch reiterated its Buy rating and $64.00 price target on Quest Diagnostics (NYSE: DGX).

BofA Merrill Lynch noted, “We were pleased to see DGX follow through on its objective to refocus on its core diagnostic services business, as we continue to believe streamlining the business model, deleveraging, and returning more to shareholders sooner is the right response to a challenging industry environment. Near term, commercial and government reimbursement pressures and light volume will pressure earnings growth, but a few years down the road, expanded health care coverage, a growing focus on outcomes based care, and substantial cost cutting and share repurchases may facilitate a return to double-digit earnings growth and an attractive ROIC profile, in our view. In the interim, our focus is on strong, continuing cash flow. We reiterate our positive outlook.”

Quest Diagnostics closed on Monday at $58.27.

Latest Ratings for DGX

DateFirmActionFromTo
Jul 2014Canaccord GenuityMaintainsHold
Jul 2014CitigroupMaintainsNeutral
May 2014Bank of AmericaUpgradesUnderperformNeutral

View More Analyst Ratings for DGX
View the Latest Analyst Ratings

Posted-In: Bank of America Merrill LynchAnalyst Color Reiteration Analyst Ratings

 

Related Articles (DGX)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters